Biotech News

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

Organogenesis (ORGO)OrganogenesisEarnings

CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today

Related news

Organogenesis

Regenerative Medicine Organogenesis develops and manufactures regenerative-medicine products used to support healing in difficult wounds and surgical procedures. Advanced Wound Care The company's wound-care portfolio includes cellular and tissue-based products, placental-derived products and other biologic matrices used in chronic and...

Recent company news

Stock data

Close
2.41 USD
Market cap
288.23M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States